rabbit anti phospho stat5 Search Results


prnat-shrna2  (GenScript corporation)
90
GenScript corporation prnat-shrna2
Prnat Shrna2, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prnat-shrna2/product/GenScript corporation
Average 90 stars, based on 1 article reviews
prnat-shrna2 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
phospho stat5 y694 rabbit mab  (Cell Signaling Technology Inc)
86
Cell Signaling Technology Inc phospho stat5 y694 rabbit mab
(A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of <t>STAT5</t> in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
Phospho Stat5 Y694 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho stat5 y694 rabbit mab/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
phospho stat5 y694 rabbit mab - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
anti-phospho-stat5 (y694) stat5a rabbit monoclonal antibody  (Boster Bio)
N/A
Boster Bio Anti-Phospho-Stat5 (Y694) STAT5A Rabbit Monoclonal Antibody catalog # P01087-1. Tested in WB, IHC applications. This antibody reacts with Human, Mouse.
   Buy from Supplier
rabbit anti-phospho-stat5 antibody  (RayBiotech)
N/A
Rabbit Anti-Phospho-Stat5 Antibody, (100 µg)
   Buy from Supplier

Image Search Results


(A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.

Journal: bioRxiv

Article Title: Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma

doi: 10.1101/2025.03.18.643177

Figure Lengend Snippet: (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.

Article Snippet: Immunoblotting was performed as previously described( Alig et al ., 2023 ) using the following primary antibodies: STAT1 Rabbit mAb (D1K9Y), STAT3 Mouse mAb (124H6), STAT6 Rabbit mAb (D3H4), AKT(pan) Rabbit mAb (C67E7), Phospho-STAT1 (Y701) Rabbit mAb (58D6), Phospho-STAT3 (Y705) Rabbit mAb (D3A7), Phospho-STAT5 (Y694) Rabbit mAb (C11C5), Phospho-STAT6 (Y641) Rabbit mAb (C11A12), Phospho-AKT (S473) Rabbit mAb (193H12), GAPDH Rabbit mAb (14C10) (all from Cell Signaling Technology, dilution 1:1000), STAT5 Rabbit polyclonalAb (C-17) (dilution 1:5000), CSF2RB (IL-3/IL-5/GM-CSFRβ Mouse mAb (A-3) (dilution 1:100) (Santa Cruz Biotechnology), followed by secondary staining using anti-Mouse (dilution 1:10000; Promega, catalog no. W4021) or Rabbit IgG (H+L) HRP conjugate (dilution 1:5000; Promega, catalog no. W4011), and detected using Amersham ECL Detection Reagents (Cytiva, catalog no. RPN3004).

Techniques: Mutagenesis, Expressing, Migration, Transwell Migration Assay, Control, Injection, Staining, Concentration Assay